The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
about
Long-term drug treatment of patients with alcohol dependenceMedications for unhealthy alcohol use: across the spectrum.Endogenous opiates and behavior: 2006Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disordersGenetic influences on response to alcohol and response to pharmacotherapies for alcoholism.College student receptiveness to various alcohol treatment optionsNaltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.Potent inhibition of alcohol self-administration in alcohol-preferring rats by a κ-opioid receptor antagonistEthanol consumption: how should we measure it? Achieving consilience between human and animal phenotypesHarm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial.Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.How adaptation of the brain to alcohol leads to dependence: a pharmacological perspective.Comparison of healthcare utilization among patients treated with alcoholism medications.Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Cognitive-behavioural therapy for individuals with bulimia nervosa and a co-occurring substance use disorderThe pharmacotherapy of alcohol dependence: a state of the art review.The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study.Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence.Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders.An inpatient treatment and discharge planning protocol for alcohol dependence: efficacy in reducing 30-day readmissions and emergency department visits.Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.Targeted naltrexone for problem drinkersReduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safetyBaseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment.Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists.Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals.Effects of naltrexone and LY255582 on ethanol maintenance, seeking, and relapse responding by alcohol-preferring (P) rats.Long-acting injectable naltrexone for the management of patients with opioid dependence.Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men.Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.Drinking to cope with negative emotions moderates alcohol use disorder treatment response in patients with co-occurring anxiety disorder.Addiction: the clinical interface.Aggregation of lifetime Axis I psychiatric disorders through age 30: incidence, predictors, and associated psychosocial outcomes.A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence
P2860
Q26773332-B7928A39-42EC-4806-8240-4D279C458EE8Q27690692-13D77E84-B77F-46B0-99DC-E505FDEF0536Q28752585-F003C925-422C-4B28-B17A-D9782F1E0CFCQ30502320-69F4FA27-17E3-45B0-B0C8-64E5E259579CQ33443427-05FDF870-3C08-4908-AA0C-620AE11F3D23Q33591091-5B5175DF-12E7-47B7-8E5C-9343ABD4A736Q33638015-FD553141-2AEE-4557-AD30-BABD583EA6A6Q33653182-BB922360-E216-4985-BA43-7E8B4340B439Q33750830-AEEDAABC-996F-406E-A0D5-B2BD81469341Q33818913-5456186F-7A16-4A91-B625-EF60B71C1C03Q33923259-F6BA7647-653E-485D-8814-A4BC74C42C90Q33949899-C8591831-3E3A-422C-BA85-DE7184200A33Q34018001-203107F1-3D6B-497B-92C7-83AF882F9637Q34073903-3A8F272A-86B3-48DE-B602-4A47717143BFQ34162896-D525046D-CB41-4DBA-8E18-A67F87999286Q34306652-81A3BCD0-6F0C-400C-A709-868638091F3DQ34344941-58BD58BB-7D9D-421D-B340-1DA80BE64440Q34543952-EEC9FF60-C707-4871-A811-D886953A4CDDQ34689570-EE606A63-7F5C-4914-91E2-F236AC73F3B0Q34711313-A8F5AEC9-58FD-45C2-B059-8B39AE6366FBQ34982437-FB8DAE4D-F8FE-419D-8827-B195EA737BB3Q35062922-621AD5C8-106F-45E4-B26A-B7D3E72B2E71Q35143623-835154B9-AA4C-4EE6-BE1B-3AC8223D9F8AQ35152511-0EB48CE9-D2D7-4420-AD62-4AE98B62756AQ35220086-868E0F4D-4E4B-4AC8-8F60-E79668DB8FAFQ35253698-FAD70D3F-DF76-49FD-B451-39B3B0D97362Q35643277-EB170C41-EB06-4AC7-B718-96E5EB39DF20Q35696834-D620D7CC-1AFA-4B33-9F80-1F08186ADC0EQ35757407-0D15DE55-535B-49FA-9A67-4434A0D1D927Q36021630-D9ED742D-58FD-4C4E-A549-DF01A70DB455Q36090024-9D172508-6222-458A-B84B-9039BEB3D50EQ36139018-F2B6E37A-82AF-4A0C-A6F2-459259FD1A51Q36223647-0A65D20A-46FB-4968-B59D-9FE3601CF99AQ36279198-DD808505-3003-43BF-A18B-8D183660F659Q36372867-E94EA6EC-D47E-4B1C-B125-F866A03ECF3FQ36642532-E6C57401-29C3-498C-A42E-948FD1513FF8Q36663528-1D267D18-27B9-481D-B757-A3C4532366D3Q36741908-E72165B5-5BB8-4147-A980-592E1E442619Q36888136-0FBC2A08-2E1D-46C8-A073-452F47D243E1Q36890264-D099665C-733B-42DB-BD3A-FE848213A09B
P2860
The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The status of naltrexone in th ...... fic effects on heavy drinking.
@ast
The status of naltrexone in th ...... fic effects on heavy drinking.
@en
type
label
The status of naltrexone in th ...... fic effects on heavy drinking.
@ast
The status of naltrexone in th ...... fic effects on heavy drinking.
@en
prefLabel
The status of naltrexone in th ...... fic effects on heavy drinking.
@ast
The status of naltrexone in th ...... fic effects on heavy drinking.
@en
P2093
P1476
The status of naltrexone in th ...... fic effects on heavy drinking.
@en
P2093
Amanda R Rabinowitz
Charles A Dackis
Charles P O'Brien
David W Oslin
Helen M Pettinati
Kyle M Kampman
Shoshana P Wortman
P304
P356
10.1097/01.JCP.0000245566.52401.20
P407
P577
2006-12-01T00:00:00Z